logo
  

Charles River Q2 Results Top Estimates

Charles River Laboratories International, Inc. (CRL) reported net income for the second quarter of $35.3 million or $0.74 per share, compared to $27.3 million or $0.57 per share for the year-ago quarter.

Income from continuing operations for the second quarter was $36.5 million or $0.75 per share, compared to $28.6 million or $0.58 per share in the prior year quarter.

Excluding items, adjusted income from continuing operations for the second quarter was $46.3 million or $0.97 per share, compared to $35.7 million or $0.73 per share in the second quarter of last year.

Total revenue for the second quarter rose 16.5% to $341.2 million from $292.9 million in the second quarter of 2013.

Analysts polled by Thomson Reuters expected the company to earn $0.82 per share on revenue of $327.74 million for the second quarter.

For the full year 2014, the company now expects net revenue growth of 9% to 11%, earnings of $2.60 to $2.70 per share and adjusted earnings of $3.25 to $3.35 per share. Previously, the company expected net revenue growth of 9% to 11%, earnings of $2.64 to $2.74 per share and adjusted earnings of $3.15 to $3.25 per share. Analysts currently expect the company to earn $3.21 per share on revenue of $327.87 million for the full year 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lincoln Park, New Jersey -based ConSup North America Inc. is recalling around 85,984 pounds of ready-to-eat or RTE sliced prosciutto ham product produced in Germany without the benefit of equivalent inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and...

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT